Conversations on Innovations in the Biopharmaceutical Pipeline
09.23.13 | By
With more than 5,000 medicines in development globally, the prospects for incredible breakthroughs in medicine – many of which may one day help those suffering from diseases that are currently untreatable – are exceedingly bright.
As the nation recognizes World Alzheimer’s Day this Saturday, the federal government announced that it is awarding a $33.2 million grant to test an Alzheimer’s medicine in pre-symptomatic seniors (60 to 75 year olds) with two copies of the AD gene. According to a
As Senior VP of Communications Matt Bennett noted on the Catalyst this week, years of hard work go into developing and testing new medicines, and this perseverance has resulted in great progress in clinical trial research.
FDA Spends $182k to Monitor Social Media While Biopharma Industry Waits for Social Media Guidance
09.20.13 | By
In this austere fiscal environment, I must admit to being a little surprised by the news that the Food and Drug Administration (FDA) is spending $182,000 on a tool to monitorwhat people are saying about the Agency on social media.
A new paper released this week highlights issues surrounding the discussions on clinical trial data & The paper Clinical Trials and Data Transparency: The Public Interest Case, highlights specific problems to the current draft European Medicines Agency (EMA). Among the problems highlighted were gaps in the protection of patient privacy, further bureaucratization of an already bureaucratic system and conflicting policies on regulatory data protection.